Therapeutic implications of macrolide resistance in pneumococcal community-acquired lower respiratory tract infections

International Journal of Clinical Practice
T J Marrie

Abstract

Macrolide anti-bacterials are widely used for the empirical treatment of lower respiratory tract infections (RTIs) due to their activity against Streptococcus pneumoniae and other common respiratory pathogens and good safety/tolerability profile. However, the prevalence of macrolide resistance, particularly pneumococcal macrolide resistance, is increasing all around the world. The mechanisms underlying macrolide resistance include efflux pump, methylase activity and, less commonly, ribosomal mutation, which produce differing levels of resistance. Growth in macrolide resistance has been linked to the increased use of these agents, and several risk factors for the development of resistance have been identified. There are emerging data to suggest that in vitro macrolide resistance may increase the likelihood of treatment failure in patients with lower RTIs. However, at present, treatment failure is rare and randomised; intervention-based trials investigating the impact of anti-bacterial resistance on clinical outcomes are lacking. Strategies to promote appropriate use of macrolides and other anti-bacterials are needed, both to maximise therapeutic impact and to minimise the development of resistance. Furthermore, there is a need f...Continue Reading

References

Mar 1, 1978·The Journal of Pediatrics·L A ChampionA D Schwartz
Jun 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·F M LaForce
May 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S MorenoE Bouza
Dec 24, 1997·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A L BarryS D Brown
Jul 24, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C Carbon
Sep 16, 1998·Clinical Therapeutics·M S NiedermanR Popovian
May 4, 1999·The Journal of Antimicrobial Chemotherapy·S Sethi
May 13, 1999·Clinical Therapeutics·M S NiedermanR Popovian
Jun 3, 1999·American Journal of Respiratory and Critical Care Medicine·S EwigJ Mensa
Sep 11, 1999·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M CizmanA Orazem
May 16, 2000·Chemotherapy·J Bartlett
Aug 19, 2000·The Journal of Infectious Diseases·B HenriquesG Källenius
Sep 13, 2000·Drugs & Aging·D Lieberman, D Lieberman
Sep 15, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J G BartlettM J Fine
Sep 15, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C FogartyK Bush
Oct 26, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G A SyrogiannopoulosN G Beratis
Oct 26, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M A KelleyM S Cohen
Oct 29, 2000·Seminars in Respiratory Infections·T M File
Nov 1, 2000·Canadian Respiratory Journal : Journal of the Canadian Thoracic Society·L A MandellUNKNOWN Canadian Thoracic Society
Jan 3, 2001·The New England Journal of Medicine·R P Wenzel, M B Edmond
Jan 13, 2001·The Medical Clinics of North America·B A Cunha
Jun 5, 2001·The Journal of Antimicrobial Chemotherapy·O A KhairR Wise
Jun 13, 2001·American Journal of Respiratory and Critical Care Medicine·M S NiedermanUNKNOWN American Thoracic Society
Jul 20, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M PihlajamäkiUNKNOWN Finnish Study Group for Antimicrobial Resistance (FiRe-Network)
Aug 29, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D M Bell
Oct 26, 2001·JAMA : the Journal of the American Medical Association·T B HydeUNKNOWN Active Bacterial Core Surveillance/Emerging Infections Program Network
Oct 16, 2001·Antimicrobial Agents and Chemotherapy·C Muller-SerieysA Andremont
Nov 20, 2001·Thorax·UNKNOWN British Thoracic Society Standards of Care Committee
Jan 26, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Clyde ThornsberryJames A Karlowsky

❮ Previous
Next ❯

Citations

Oct 6, 2007·International Journal of Clinical Practice·O YetkinH Gunen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.